Introduction Moxidectin is a milbemycin endectocide recently approved for the treatment of
human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a …

This review summarises more than a century of research on onchocerciasis, also known as
river blindness, and its control. River blindness is an infection caused by the tissue filaria …

Background The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease
that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and …

In the context of stalling progress against malaria, resistance of mosquitoes to insecticides,
and residual transmission, mass drug administration (MDA) of ivermectin, an endectocide …

Background Treatment of onchocerciasis using mass ivermectin administration has reduced
morbidity and transmission throughout Africa and Central/South America. Mass drug …

Background A high epilepsy prevalence has been reported in several onchocerciasis-
endemic villages along the Mbam and Sanaga river valleys in Cameroon, including Bilomo …

Background Mass drug administration (MDA) with ivermectin is the cornerstone of efforts to
eliminate human onchocerciasis by 2020 or 2025. The feasibility of elimination crucially …

Onchocerciasis is the leading cause of blindness and severe skin lesions which remain a
major public health problem, especially in tropical areas. The widespread use of antibiotics …

National programs in Africa have expanded their objectives from control of onchocerciasis
(river blindness) as a public health problem to elimination of parasite transmission …

Onchocerciasis and lymphatic filariasis are targeted for elimination, primarily using mass
drug administration at the country and community levels. Elimination of transmission is the …